MedTrace Logo

Efficacy of Artesunate-amodiaquine and Artemether-lumefantrine for Treatment of Plasmodium Falciparum Malaria in Liberia

NCT06300970 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 352

Last updated 2024-05-07

No results posted yet for this study

Summary

To assess the efficacy of both first-line antimalarial medications used for the treatment of uncomplicated Plasmodium falciparum malaria infections in two geographic regions in Liberia.

Conditions

  • Plasmodium Falciparum
  • Malaria
  • Uncomplicated Malaria

Interventions

DRUG

Amodiaquine-artesunate (ASAQ)

Oral medication given for treatment of uncomplicated plasmodium falciparum infection.

DRUG

Artemether+Lumefantrine (AL)

Oral medication given for treatment of uncomplicated plasmodium falciparum infection.

Sponsors & Collaborators

Principal Investigators

  • Victor S Koko · Liberia National Malaria Control Program

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
6 Months
Max Age
59 Months
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-08-09
Primary Completion
2023-08-16
Completion
2023-08-16

Countries

  • Liberia

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06300970 on ClinicalTrials.gov